Drug Profile
Research programme: soluble CD83 - Argos Therapeutics/Beckman Coulter
Alternative Names: AGS-010; sCD83Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Beckman Coulter
- Developer Argos Therapeutics Inc
- Class CD antigens; Immunoglobulins; Membrane glycoproteins; Recombinant proteins
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders; Transplant rejection
Highest Development Phases
- No development reported Autoimmune disorders; Transplant rejection
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Transplant-rejection in USA (Ophthalmic, Drops)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Transplant-rejection in USA (Parenteral)